Mezagitamab, an anti-CD38 Monoclonal Antibody, Stabilizes eGFR 18 months Off Treatment in IgAN

What it is about

Who published it, and when

How it spread - 6 original reports

1. Fri, 23 October 2026

   3 reports
   • hcplive.com09:39
     Mezagitamab, an anti-CD38 Monoclonal Antibody, Stabilizes eGFR 18 months Off Treatment in IgAN

     Final 96-week phase 1b data show sustained UPCR reduction and stable eGFR about 1.5 years after the last mezagitamab dose, with no serious adverse events.

   • hcplive.com10:05first to report
     Sibeprenlimab Stabilizes eGFR Over 24 Months in IgA Nephropathy: VISIONARY

     Final VISIONARY data show sibeprenlimab held eGFR steady over 24 months, with a 4.5 mL/min/1.73 m² per year slope advantage and fewer kidney outcome events vs placebo.

   • hcplive.com10:18
     Kidney Compass: ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy

     Jonathan Barratt, PhD, FRCP, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack final ORIGIN 3 eGFR data for atacicept in IgAN.

2. Sat, 24 October 2026

   2 reports
   • hcplive.com01:02
     IMAgINATION: Sefaxersen Meets Phase 3 Proteinuria Endpoint in IgA Nephropathy

     Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.

   • hcplive.com01:50
     Pentoxifylline in Diabetic Kidney Disease: What the Evidence Shows

     Rajiv Agarwal, MD, MS, explains why decades of pentoxifylline data in DKD remain inconclusive and how the VA PTXRx trial aims to settle the question.

3. Tue, 27 October 2026

   1 report
   • ajmc.com17:45
     Povetacicept Cuts Proteinuria in IgAN: Richard Lafayette, MD, FACP

     Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings.